People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Subscribe To Our Newsletter & Stay Updated
